Guidance on Biosimilar Submission Requirements in Canada

Published date09 December 2016
Law FirmGoodwin
Subject MatterFDA,Biosimilars,Canada,Regulatory Agencies,Pharmaceutical Industry,Health Canada,European Medicines Agency (EMA)

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT